dc.contributor.author |
Báez Cabanillas, María Victoria |
|
dc.contributor.author |
Colque, Roberto |
|
dc.contributor.author |
Tibaldi, Miguel Ángel |
|
dc.contributor.author |
Kaplinsky, Edgardo |
|
dc.contributor.author |
Perrone, Sergio Víctor |
|
dc.contributor.author |
Barbagelata, Alejandro |
|
dc.date.accessioned |
2023-03-01T17:33:40Z |
|
dc.date.available |
2023-03-01T17:33:40Z |
|
dc.date.issued |
2023-01-04 |
|
dc.identifier.citation |
Báez Cabanillas, M.V., Colque, R., Tibaldi, M.Á., Kaplinsky, E., Perrone, S., Barbagelata, A., 2023. Emerging concepts in heart failure management and treatment: focus on tachycardia-induced cardiomyopathy. Drugs Context 12, 2022-8–4. https://doi.org/10.7573/dic.2022-8-4 |
es_ES |
dc.identifier.uri |
https://doi.org/10.7573/dic.2022-8-4 |
|
dc.identifier.uri |
https://repositorio.fleni.org.ar/xmlui/handle/123456789/793 |
|
dc.description.abstract |
Tachycardia-induced cardiomyopathy is an entity characterized by reversible dysfunction of the left ventricle, which can be induced by different types of arrhythmia such as atrial fibrillation, atrial flutter, incessant supraventricular tachycardia and ventricular arrhythmia (more frequent causes). Correct identification of the causative arrhythmia and normalization of the heart rate (e.g through medical treatment, electrical cardioversion, ablation) can lead to recovery of left ventricular function. Tachycardia-induced cardiomyopathy should be suspected in patients with tachycardia and left ventricular dysfunction (heart failure setting), especially when there is no history of previous heart disease. Its usual phenotype is that of non-ischaemic/non-valvular dilated cardiomyopathy and it can occur in both children (main cause: permanent junctional reciprocating tachycardia) and adults (main cause: atrial fibrillation). With proper treatment, most cases recover within a few months, though there is a risk of relapse, especially when the causal arrhythmia reappears or its control is lost. This is a narrative review that comprehensively addresses the pathophysiology, clinical manifestations, and therapeutic management of tachycardia-induced cardiomyopathy. |
es_ES |
dc.language.iso |
eng |
es_ES |
dc.publisher |
Bioexcel Publishing |
es_ES |
dc.rights |
info:eu-repo/semantics/openAccess |
|
dc.subject |
Atrial Fibrillation |
es_ES |
dc.subject |
Fibrilación Atrial |
es_ES |
dc.subject |
Cardiomiopatía |
es_ES |
dc.subject |
Cardiomyopathy |
es_ES |
dc.subject |
Insuficiencia Cardíaca |
es_ES |
dc.subject |
Heart Failure |
es_ES |
dc.subject |
Taquicardia |
es_ES |
dc.subject |
Tachycardia |
es_ES |
dc.title |
Emerging concepts in heart failure management and treatment: focus on tachycardia-induced cardiomyopathy |
es_ES |
dc.type |
info:eu-repo/semantics/article |
es_ES |
dc.type |
info:eu-repo/semantics/publishedVersion |
|
dc.description.fil |
Fil: Báez Cabanillas, María Victoria. Universidad Católica Argentina; Argentina. |
|
dc.description.fil |
Fil: Colque, Roberto. Sanatorio Allende; Argentina. |
|
dc.description.fil |
Fil: Tibaldi, Miguel Ángel. Sanatorio Allende; Argentina. |
|
dc.description.fil |
Fil: Kaplinsky, Edgardo. Hospital Municipal de Badalona; España. |
|
dc.description.fil |
Fil: Perrone, Sergio Víctor. Fleni. Departamento de Neurología. Servicio de Cardiología; Argentina. |
|
dc.description.fil |
Fil: Barbagelata, Alejandro. Universidad Católica Argentina; Argentina. |
|
dc.relation.ispartofCOUNTRY |
Reino Unido |
|
dc.relation.ispartofCITY |
Londres |
|
dc.relation.ispartofTITLE |
Drugs in context |
|
dc.relation.ispartofISSN |
1740-4398 |
|
dc.type.snrd |
info:ar-repo/semantics/artículo |
es_ES |